Bupropion shows benefit for cancer-related fatigue in cancer survivors
Published on 1 June 2026
At ASCO 2026 Dr Luke Peppone talks to ecancer about findings from a phase III trial evaluating bupropion for the treatment of moderate to severe cancer-related fatigue in patients who had completed surgery, radiotherapy, and/or intravenous anticancer therapy.
The study demonstrated significant improvements in fatigue symptoms with bupropion compared with placebo, supporting its potential use as a treatment option for cancer-related fatigue in clinical practice.